DS-3201b

DRUG5 trials

Conditions

Hepatic ImpairmentLeukemia, Lymphocytic, AcuteLeukemia, Myeloid, AcuteLymphoma, MalignantNon-hodgkin LymphomaSmall Cell Lung Cancerpediatric, adolescent and young adult patient with malignant solid tumors Malignant solid tumors

Phase 1

DS-3201b in Participants With Lymphomas

Active, not recruitingNCT02732275

Daiichi Sankyo Co., Ltd.Lymphoma, Malignant, Non-hodgkin Lymphoma

Start: 2016-03-31End: 2027-12-31Target: 100Updated: 2026-04-28

DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

TerminatedNCT03110354

Daiichi SankyoLeukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute

Start: 2017-04-05End: 2021-03-09Updated: 2024-01-31

DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer

TerminatedNCT03879798

Memorial Sloan Kettering Cancer CenterSmall Cell Lung Cancer

Start: 2019-03-15End: 2023-05-02Updated: 2024-10-10

Study of Single-dose DS-3201b in Participants With Hepatic Impairment

CompletedNCT04276662

Daiichi SankyoHepatic Impairment

Start: 2019-11-21End: 2021-02-23Updated: 2021-02-25

NCCH1904/MK007 trial

Active, not recruitingJPRN-jRCT2031190268

Arakawa Ayumupediatric, adolescent and young adult patient with malignant solid tumors Malignant solid tumors

Start: 2020-03-25Target: 30Updated: 2026-06-29

2025-11-01

Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin Lymphoma.

2025-11-01

Safety and efficacy of the EZH1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric patients with malignant solid tumors (NCCH1904): A multicenter phase I trial.

Journal of Clinical Oncology2025-05-281 citations

Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study.

2024-10-2918 citations

Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results from a Phase 1 Trial

Blood2023-11-025 citations

Valemetostat for Relapsed or Refractory B-Cell Lymphomas: Primary Results from a Phase 1 Trial

Blood2023-11-024 citations

Durable Clinical Impacts and Mechanisms of Action and Resistance in EZH1/2-Targeting Epigenetic Therapy

Blood2022-11-15

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

Blood2022-09-23146 citations

Trial in progress: A phase I trial of dual EZH 1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric, adolescent, and young adult patients with malignant solid tumors.

Journal of Clinical Oncology2022-06-013 citations

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Blood2019-11-1316 citations

Anti-Tumor Effect of the EZH1/2 Dual Inhibitor Valemetostat Against Diffuse Large B-Cell Lymphoma Via Modulation of B-Cell Receptor Signaling and c-Myc Signaling Pathways

Blood2019-11-134 citations

DS-3201, a Potent EZH1/2 Dual Inhibitor, Demonstrates Antitumor Activity Against Non-Hodgkin Lymphoma (NHL) Regardless of EZH2 Mutation

Blood2018-11-2912 citations

DS-3201b

Sponsors

Conditions

Phase 1

Related Papers